Clinical Trial Update: Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of ixazomib and pevonedistat in patients with recurrent or refractory multiple myeloma has completed enrollment with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2023-09-06